Cartesian Therapeutics (RNAC) Net Income towards Common Stockholders (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$25.5 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$25.5 million, down 28.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$109.1 million (down 120.3% YoY), and the FY2025 annual result was -$130.3 million, down 68.27% from the prior year.
• Net Income towards Common Stockholders climbed to -$25.5 million in Q1 2026 per RNAC's latest filing, from -$77.4 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $13.4 million in Q2 2022 and troughed at -$196.7 million in Q4 2023.
• A 5-year average of -$22.6 million and a median of -$12.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders jumped 5505.67% in 2022, then tumbled 3437.15% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $5.9 million in 2022, then plunged by 3437.15% to -$196.7 million in 2023, then soared by 87.66% to -$24.3 million in 2024, then plunged by 218.7% to -$77.4 million in 2025, then surged by 67.08% to -$25.5 million in 2026.
• Business Quant data shows RNAC's Net Income towards Common Stockholders at -$25.5 million in Q1 2026, -$77.4 million in Q4 2025, and -$19.5 million in Q3 2025.